Based on momentum from COVID-19 vaccine research, Trial Management Associates, an "integrated site network" based in Wilmington, North Carolina, recently announced the research center's involvement in a major respiratory syncytial virus (RSV) study. The trial site acknowledges that COVID-19 vaccine study participation has led to the opportunity to expand its vaccine research presence. Presently, there is no approved vaccine for RSV, TMA couldn't name the large industry sponsor due to confidentiality agreements, but TrialSite research suggests GlaxoSmithKline sponsors the study. TrialSite below provides a breakdown of the RSV vaccine pipeline and a summary of this Wilmington-based trial site organization, Trial Management Associates. While pharmaceutical companies invest in drug and vaccine development, trial site organizations conduct the actual research, led by the site's principal investigator. And without the participation of people living in communities such as Wilmington, North Carolina, no advancements in drugs and vaccines would ever occur.
RSV—What is It?
According to the Centers for Disease Control and Prevention (CDC), and the World Health Organization (WHO),...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).